Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Treasury Shares (2022 - 2025)

Historic Treasury Shares for SAB Biotherapeutics (SABS) over the last 4 years, with Q3 2025 value amounting to $5.5 million.

  • SAB Biotherapeutics' Treasury Shares changed 0.0% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $5.5 million for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, SAB Biotherapeutics' Treasury Shares stood at $54665.0, which was up 20000.0% from -$54665.0 recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Treasury Shares high stood at $546658.0 for Q1 2022, and its period low was -$54665.0 during Q4 2023.
  • Moreover, its 4-year median value for Treasury Shares was $54665.0 (2022), whereas its average is $207730.2.
  • The largest annual percentage gain for SAB Biotherapeutics' Treasury Shares in the last 5 years was 0.0% (2023), contrasted with its biggest fall of 0.0% (2023).
  • SAB Biotherapeutics' Treasury Shares (Quarter) stood at $5.5 million in 2022, then changed by 0.0% to $5.5 million in 2023, then changed by 0.0% to $5.5 million in 2024, then changed by 0.0% to $5.5 million in 2025.
  • Its last three reported values are $5.5 million in Q3 2025, $5.5 million for Q2 2025, and $5.5 million during Q1 2025.